Cyteir Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Cyteir Therapeutics, Inc. | CYT - NASDAQ |
$16.00-$18.00 | $18.00 | $16.50 | 7.4 million | 6/18/2021 |
| JP Morgan, Morgan Stanley, BofA Securities | ||||||
Co-Manager(s): Wedbush PacGrow
| ||||||
| Health Care | ||||||
Filing(s): Filed 2021-05-28 Terms Added 2021-06-14 | ||||||
Cyteir Therapeutics, Inc. Quote & Chart - Click for current quote - CYT
IPO Boutique aggregates information on public companies and private companies, such as "CYT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Cyteir Therapeutics, Inc. (adapted from Cyteir Therapeutics, Inc. prospectus):
They are a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit deoxyribonucleic acid, or DNA, damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit deoxyribonucleic acid, or DNA, damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "CYT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.